The invention relates to inhalation powder formulations containing enantiomerically pure beta-agonists of formula (1), wherein the radicals R<；1>；, R<；2>；, R<；3>； and R<；4 >；are defined as in claims and descriptions and are optionally embodied in the form the pharmaceutically acceptable acid addition salts thereof and are optionally combined with a pharmaceutically acceptable accessory agent. A method for producing said formulations and the use thereof in the form of a drug, in particular as a drug for treating respiratory tract diseases are also disclosed.
